A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery
- PMID: 1260682
- DOI: 10.1002/1097-0142(197604)37:4<1648::aid-cncr2820370405>3.0.co;2-3
A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery
Abstract
Since 1968, there have been 62 patients with stomach cancer seen in the First Department of Surgery of Chiba University. Treatment consisted of preoperative intra-arterial chemotherapy and surgery. The chemotherapy entailed continuous infusion for 15 to 20 hours. The survival rates were analyzed with particular emphasis on the degree of serosal invasion of the stomach. The overall survivals at the end of 3 years were 54.2% for the treated patients, and 37.1% for the controls: and at the end of 5 years, 33.3% of the treated patients were living as compared to 29.7% of the control patients. In patients without serosal invasion, the survival rates were higher for those treated than for the controls for the first 2 years. At the end of 3 years, the 39 patients treated for serosal invasion had a survival rate of 46.8% vs. 29% in the controls: and at 5 years, 32.2% of the treated patients vs. 23.7% in the controls. The survival rates for the treated patients with cancerous infiltration of other organs were about the same as those for the corresponding control patients.
Similar articles
-
[Preoperative cancer chemotherapy for gastric cancer].Gan To Kagaku Ryoho. 1985 May;12(5):1010-8. Gan To Kagaku Ryoho. 1985. PMID: 3922306 Japanese.
-
Role of surgery in the patients with stage I and II primary gastric lymphoma.Hepatogastroenterology. 2003 May-Jun;50(51):877-82. Hepatogastroenterology. 2003. PMID: 12828109
-
Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion.J Chin Med Assoc. 2013 Aug;76(8):425-31. doi: 10.1016/j.jcma.2013.04.004. Epub 2013 Jun 22. J Chin Med Assoc. 2013. PMID: 23796652
-
Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?World J Gastroenterol. 2018 Jan 14;24(2):274-289. doi: 10.3748/wjg.v24.i2.274. World J Gastroenterol. 2018. PMID: 29375213 Free PMC article. Review.
-
Surgery and adjuvant chemotherapy for gastric cancer.Hepatogastroenterology. 1989 Apr;36(2):79-85. Hepatogastroenterology. 1989. PMID: 2659483 Review.
Cited by
-
Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer.Ann Surg. 1977 Apr;185(4):462-6. doi: 10.1097/00000658-197704000-00016. Ann Surg. 1977. PMID: 320951 Free PMC article. Clinical Trial.
-
Treatment of multiple liver metastasis from gastric carcinoma.World J Surg Oncol. 2007 Jun 21;5:70. doi: 10.1186/1477-7819-5-70. World J Surg Oncol. 2007. PMID: 17584926 Free PMC article.
-
R0 resection in the treatment of gastric cancer: room for improvement.World J Gastroenterol. 2010 Jul 21;16(27):3358-70. doi: 10.3748/wjg.v16.i27.3358. World J Gastroenterol. 2010. PMID: 20632437 Free PMC article.
-
The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.Int J Surg Oncol. 2013;2013:781742. doi: 10.1155/2013/781742. Epub 2013 Sep 17. Int J Surg Oncol. 2013. PMID: 24163764 Free PMC article.
-
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.Eur J Med Res. 2022 Nov 9;27(1):239. doi: 10.1186/s40001-022-00878-7. Eur J Med Res. 2022. PMID: 36352476 Free PMC article.